← Search & browse all drugs

betamethasone

D07AC01

Forms & Strengths

Cream 0.05%
Ointment 0.05%
Lotion 0.05%
Topical Gel 0.05%
Scalp Application 0.05%

Adult Dosing

Apply thin film to affected skin areas 1 to 2 times daily
Limit use to continuous periods of no more than 2 consecutive weeks
Maximum weekly dose should not exceed 50 g of the 0.05% formulation

Pediatric Dosing

Safety and efficacy in pediatric patients under 12 years are not well established
If used in children, apply sparingly to the smallest effective area for the shortest duration
Avoid use in diaper dermatitis and under occlusive diapers

Indications

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Psoriasis vulgaris
Atopic dermatitis
Contact dermatitis and eczema

Mechanism of Action

High-potency topical corticosteroid
Induces phospholipase A2 inhibitory proteins (lipocortins)
Suppresses the release of arachidonic acid, reducing the formation of inflammatory mediators like prostaglandins and leukotrienes
Vasoconstrictive and immunosuppressive properties in dermal tissues

Contraindications

Hypersensitivity to betamethasone or other corticosteroids
Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella)
Rosacea and perioral dermatitis
Ophthalmic use

Adverse Reactions

Local: Burning, pruritus, irritation, dryness, folliculitis, hypertrichosis
Skin atrophy, striae, telangiectasia, purpura
Hypopigmentation or secondary infection
Systemic (with prolonged use or occlusion): Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia

Drug Interactions

Co-administration with strong CYP3A4 inhibitors may increase systemic exposure and risk of HPA axis suppression
Concomitant use with other systemic immunosuppressants may enhance immunosuppressive effects
Potential decreased efficacy when used concurrently with topical enzyme inducers

Curated Content: Needs Vetting Before Put to Clinical Use